---
annotation-target: 1-s2.0-S0006497122010655-main.pdf
---


>%%
>```annotation-json
>{"created":"2022-09-13T09:47:49.016Z","updated":"2022-09-13T09:47:49.016Z","document":{"title":"TARGETING FLT3 BY NEW-GENERATION ANTIBODY-DRUG-CONJUGATE IN COMBINATION WITH KINASE INHIBITORS FOR TREATMENT OF AML","link":[{"href":"urn:x-pdf:dc0abbc4df348eb13151e6cbd7a7accb"},{"href":"vault:/hematology-theroy/papers/20220831/1-s2.0-S0006497122010655-main.pdf"}],"documentFingerprint":"dc0abbc4df348eb13151e6cbd7a7accb"},"uri":"vault:/hematology-theroy/papers/20220831/1-s2.0-S0006497122010655-main.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220831/1-s2.0-S0006497122010655-main.pdf","selector":[{"type":"TextPositionSelector","start":158,"end":233},{"type":"TextQuoteSelector","exact":"NEW-GENERATION ANTIBODY-DRUG-CONJUGATE IN COMBINATION WITHKINASE INHIBITORS","prefix":"hematology.orgTARGETING FLT3 BY ","suffix":" FOR TREATMENT OF AML Tracking n"}]}]}
>```
>%%
>*%%PREFIX%%hematology.orgTARGETING FLT3 BY%%HIGHLIGHT%% ==NEW-GENERATION ANTIBODY-DRUG-CONJUGATE IN COMBINATION WITHKINASE INHIBITORS== %%POSTFIX%%FOR TREATMENT OF AML Tracking n*
>%%LINK%%[[#^u6580409i4n|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^u6580409i4n
